WO1999035145A1 - Deprotection and recrystallization processes - Google Patents
Deprotection and recrystallization processes Download PDFInfo
- Publication number
- WO1999035145A1 WO1999035145A1 PCT/US1998/026443 US9826443W WO9935145A1 WO 1999035145 A1 WO1999035145 A1 WO 1999035145A1 US 9826443 W US9826443 W US 9826443W WO 9935145 A1 WO9935145 A1 WO 9935145A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- oxo
- lactam
- acid
- amino
- Prior art date
Links
- 0 CC(CCc1cccc2c1N1C3(CC3)*2)(C1=O)NC Chemical compound CC(CCc1cccc2c1N1C3(CC3)*2)(C1=O)NC 0.000 description 13
- IFTRQJLVEBNKJK-UHFFFAOYSA-N CCC1CCCC1 Chemical compound CCC1CCCC1 IFTRQJLVEBNKJK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the lactam can be a moncyclic, fused bicyclic or fused tricyclic as taught by Karanewsky et al . in U.S. Patent 5,552,397, Karanewsky in U.S. Patent 5,504,080, Robl in U.S. Patent 5,508,272, Robl in U.S. Patent 5,525,723, Robl in U.S. Patent 5,362,727, Robl in U.S. Patent 5,587,375, Robl et al. in U.S. Serial No. 443,278 filed May 17, 1995 and EP 744,319, Ryono et al . in U.S. Patent 5,635,504 and Karanewsky et al . in U.S. Patent 5,650,408.
- This invention is directed to an improvement in the deprotection processes used to convert an acylmercaptoalkanoylamino lactam acid or ester of the formula
- Such disulfides are themselves an unwanted impurity in the pharmaceutically active mercaptoalkanoylamino lactam acid products of formula I.
- the disulfides of formula III can convert to other undesirable side-products.
- R x is other than hydrogen
- the disulfide of formula III can convert to the mercaptoalkanoyl lactam of formula I having the undesired chirality at the optically active carbon in the mercaptoalkanoyl sidechain.
- the formation of the disulfide impurity of formula III can occur during recrystallization of the mercaptoalkanoylamino lactam product of formula I .
- the improvements of this invention reside in including within the above deprotection and recrystallization processes an agent that minimizes the amount of the disulfides of formula III and, in turn, minimizes the formation of the undesired epimer of the pharmaceutically active compound of formula I.
- Preferred agents for this purpose are bismercaptans as well as reducing agents such as phosphines and phosphites, zinc metal powder, and sodium hydrosulfite.
- amino lactam acids and esters Xi shown above include :
- Rl and R2 are independently selected from straight or branched chain alkyl of 1 to 6 carbons, - (CH2) _ a-ryl, - (CH2)m -su kstituted aryl, or - (CE-2 ) m-heteroaryl .
- m is zero or an integer from 1 to 6.
- n is zero or one.
- R4 and R5 are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, - (CH2 )m-cycloalkyl, ⁇ (CH2) ⁇ r ⁇ ar -/l/ - (CH2)m ⁇ substituted aryl, or
- R4 and R5 is hydrogen and the other is hydroxy, or R4 and R5 taken together with the carbon to which they are attached complete a saturated cycloalkyl ring of 3 to 7 carbons, or R4 and R5 taken together with the carbon to which they are attached complete a keto substituent.
- R ⁇ , R8 and Rio are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, -(CH2) m -cycloalkyl, - (CH2) m -aryl, - (CH2)m-substituted aryl, or - ( CH2 ) m ⁇ heteroaryl •
- R7, Rg and Rn are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, - (CH2)m _ cycloalkyl, - (CH2)m-aryl, - (CH2)m-subsituted aryl, or - (CH2) m _ h e teroaryl or R ⁇ and R7 taken together with the carbon to which they are attached complete a saturated cycloalkyl ring of 3 to 7 carbons, or Rs and R9 taken together with the carbon to which they are attached complete a saturated cycloalkyl ring of 3 to 7 carbons .
- b is zero or one.
- d is zero or one.
- q is an integer from 1 to 4.
- r is one or two.
- t is an integer from 1 to 3.
- v is one or two.
- w is one or two.
- Yi is -CH2-, -(CH2)2-. "(CH 2 )3-- -0- , -S-, -CH 2 -0-, or -CH2-S-.
- Y2 is -CH2- -S-, or -0- .
- Y3 is -CH2-, -(CH 2 )2, -(CH 2 )3-, "0- or -CH2-0-.
- R17 is hydrogen, alkyl, substituted alkyl, alkenyl,
- Y5 is -CH2-, -S-, or -0- provided that Y5 is -S- or
- Y ⁇ is -S- or -0- .
- the dashed line represents an optional double bond between the two carbons .
- Y7 is -S- or -NH- .
- Y8 is -S-, -O- or -NH- .
- Ri8 and R19 are independently selected from hydrogen, alkyl, - (CH2)m ⁇ a-ryl, or Ri8 and R19 together with the carbon and nitrogen atoms to which they are attached complete a five or six membered ring.
- Rl2 is hydrogen or an acid protecting group such as methyl , ethyl , propyl , phenyl or benzyl .
- alkyl refers to straight or branched radicals of 1 to 7 carbons, preferably 1 to 4 carbons.
- substituted alkyl refers to such straight or branched chain radicals of 1 to 7 carbons wherein one, two or three hydrogens have been replaced by a hydroxy, amino, cyano, Cl, Br, F, trifluoromethyl, -NH (alkyl of 1 to 4 carbons), -N(alkyl of 1 to 4 carbons) 2, alkoxy of 1 to 4 carbons, alkylthio of 1 to 4 carbons, or carboxy.
- the preferred "substituted alkyl” is of 1 to 4 carbons with one hydrogen replaced by hydroxy, a ino, Cl, or Br.
- alkenyl refers to straight or branched chain radicals of 3 to 7 carbon atoms having one or two double bonds. Preferred “alkenyl” groups are straight chain radicals of 3 to 5 carbons having one double bond.
- cycloalkyl refers to saturated rings of 3 to 7 carbons with cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl being preferred.
- aryl refers to phenyl, 1-naphthyl and 2-naphthyl with phenyl being preferred.
- substituted aryl refers to phenyl
- 1-naphthyl and 2-naphthyl having a substituent selected from alkyl of 1 to 4 carbons, alkoxy of 1 to 4 carbons, alkylthio of 1 to 4 carbons, Cl, Br, F, hydroxy, trifluoromethyl, amino, - H(alkyl of 1 to 4 carbons), or -N (alkyl of 1 to 4 carbons) 2 di and tri-substituted phenyl, 1-naphthyl, or 2-naphthyl wherein said substituents are selected from methyl, methoxy, Cl, Br, methylthio, hydroxy or amino.
- heteroaryl refers to unsaturated rings of 5 or 6 atoms containing one or two 0 and S atoms and/or one to four N atoms provided that the total number of hetero atoms in the ring is 4 or less.
- the heteroaryl ring is attached by way of an available carbon or nitrogen atom.
- Preferred heteroaryl groups include 2-, 3-, or 4-pyridyl, 4-imidazolyl, 4-thiazolyl, 2- and 3-thienyl and 2- and 3-furyl.
- the term heteroaryl also includes bicyclic rings wherein the five or six membered ring containing 0, S and N atoms as defined above is fused to a benzene or pyridyl ring.
- Preferred bicyclic rings are 2- and 3-indolyl and 4- and 5-quinolinyl.
- acylmercaptoamino lactam esters of formula II are prepared by coupling the acylmercapto containing sidechain of the formula
- the above reaction can be performed in an organic solvent such as methylene chloride and in the presence of a coupling reagent such as l-ethyl-3- (3-dimethylaminopropyl) carbodiimide, dicyclohexylcarbodiimide, benzotriazol-1-yloxytris- (dimethylamino) phosphonium hexafluorophosphate, or carbonyldiimidazole .
- a coupling reagent such as l-ethyl-3- (3-dimethylaminopropyl) carbodiimide, dicyclohexylcarbodiimide, benzotriazol-1-yloxytris- (dimethylamino) phosphonium hexafluorophosphate, or carbonyldiimidazole .
- the acylmercapto carboxylic acid of formula XXIV can be converted to an activated form such as an acid chloride, mixed anhydride
- the deprotection processes of this invention include conversion of the acylmercaptoalkanoylamino lactam acid or ester of formula II to the mercaptoalkanoylamino lactam of formula I
- the improvement in this process resides in including in the basic hydrolysis reaction that removes the acyl functional group R 2 -C(0)- an agent that minimizes the amount of the disulfides of formula III and, in turn, minimizes the formation of the undesired epimer of the pharmaceutically active compound of formula I.
- acylmercaptoalkanoylamino lactam of formula II is a carboxylic acid, i.e. R12 in the definition of Xi in formula II is hydrogen
- the acyl protecting group R2 ⁇ C(0)- is removed in a single step to give the pharmaceutically active lactam of formula I.
- This deprotection process involves treating the lactam carboxylic acid of formula II with an alkali metal or alkaline earth metal hydroxide or carbonate or with an amine in a suitable solvent containing a sufficient amount of an agent that minimizes the amount of the disulfides of formula III.
- Suitable agents for this purpose include bismercaptans as well as phosphine and phosphite reducing agents, zinc metal powder, and sodium hydrosulfite. Such agents can be present in an amount from about 1 mole to about 20 mole percent, preferably from about 5 mole percent to about 10 mole percent in the reaction mixture.
- This deprotection reaction can be performed at a temperature of from about -20°C to about 45°C.
- the reaction is acidified with an aqueous acid such as HC1 acetic acid, propanoic acid, sulfuric acid, phosphoric acid, or oxalic acid to precipitate out the pharmaceutically active lactam of formula I .
- Suitable alkali metal and alkaline earth metal hydroxides and carbonates for this deprotection process include sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate, and lithium carbonate.
- Amines useful in this deprotection process include H2N-alkyl, H2N- (CH2)m _ aryl, and hydroxyalkylamines wherein alkyl , aryl , and m are as defined above. Methylamine, ethylamine, benzylamine, and ethanolamine are preferred.
- Suitable solvents for this deprotection process include methanol, aqueous methanol, ethanol, aqueous ethanol, tetrahydrofuran, aqueous tetrahydrofuran, isopropanol, aqueous isopropanol, acetonitrile, aqueous acetonitrile and water.
- acylmercaptoalkanoylamino lactam of formula II is a carboxylic acid ester, i.e. R12 in the definition of Xi in formula II is an acid protecting group such as methyl, ethyl, propyl, phenyl or benzyl, then the acyl protecting group R2-C(0)- and the carboxylic acid protecting group can be removed in a single step or in two steps to give the pharmaceutically active lactam of formula I.
- the lactam carboxylic acid ester of formula II is treated under aqueous conditions with an alkali metal or alkaline earth metal hydroxide or carbonate in a suitable solvent containing a sufficient amount of an agent that minimizes the amount of the disulfides of formula III.
- Suitable agents for this purpose include bismercaptans as well as phosphine and phosphite reducing agents, zinc metal powder, and sodium hydrosulfite. Such agents can be present in an amount from about 1 mole percent to about 20 mole percent, preferably from about 5 mole percent to about 10 mole percent in the reaction mixture.
- This deprotection reaction can be performed at a temperature of from about -20° to about 45°C.
- reaction is acidified with an aqueous acid such as HCl, acetic acid, propanoic acid, sulfuric acid, phosphoric acid, or oxalic acid to precipitate out the pharmaceutically active lactam of formula I .
- aqueous acid such as HCl, acetic acid, propanoic acid, sulfuric acid, phosphoric acid, or oxalic acid
- Suitable alkali metal and alkaline earth metal hydroxides and carbonates for this one step deprotection process are as defined above.
- Suitable solvents for this one step deprotection process include methanol, ethanol, isopropanol, acetonitrile, and tetrahydrofuran. This reaction is performed under aqueous conditions meaning that water is present in the solvent and/or in the reagents.
- the improved deprotection processes of this invention also include the process in which the acylmercaptoalkanoylamino lactam ester of formula II is converted to the mercaptoalkanoylamino lactam ester of formula I.
- This process involves removal of the acyl group R2 _ C(0)- by treating the acylmercaptoalkanoylamino lactam ester of formula II with an alkali metal or alkaline earth hydroxide or carbonate or with an amine in a suitable solvent containing a sufficient amount of an agent that minimizes the amount of the disulfides of formula III and, in turn, minimizes the formation of the undesired epimer of the pharmaceutically active compound of formula I.
- Suitable agents for this purpose include bismercaptans as well as phosphine and phosphite reducing agents, zinc metal powder, and sodium hydrosulfite. Such agents can be present in an amount from about 1 mole percent to about 20 mole percent, preferably from about 5 mole percent to about 10 mole percent in the reaction mixture.
- an alkali metal or alkaline earth metal hydroxide or carbonate is employed, the reaction is performed under non-aqueous conditions.
- an amine is employed, the reaction is performed under aqueous conditions . This deprotection reaction is performed at a temperature of from about -20°C to about 45°C.
- reaction is acidified with an aqueous acid such as HCl, acetic acid, propanoic acid, sulfuric acid, phosphoric acid, or oxalic acid to precipitate out the mercaptoalkanoylamino lactam ester of formula I .
- an aqueous acid such as HCl, acetic acid, propanoic acid, sulfuric acid, phosphoric acid, or oxalic acid to precipitate out the mercaptoalkanoylamino lactam ester of formula I .
- Suitable alkali metal and alkaline earth metal hydroxides and carbonates and amines for this first deprotection step are as defined above.
- Suitable solvents include methanol, ethanol, isopropanol, acetonitrile, and tetrahydrofuran.
- the improved deprotection processes of this invention also include the process in which the mercaptoalkanoylamino lactam ester of formula I is converted to the pharmaceutically active mercaptoalkanoylamino lactam of formula I wherein R 12 is hydrogen.
- This process involves removal of the carboxylic acid protecting group by treating the lactam ester of formula I with an alkali metal or alkaline earth metal hydroxide or carbonate under aqueous conditions in a suitable solvent containing a sufficient amount of an agent that minimizes the amount of the disulfide of formula III, and in turn, minimizes the formation of the undesired epimer of the pharmaceutically active compound of formula I .
- Suitable agents for this purpose include bismercaptans as well as phosphine and phosphite reducing agents, and zinc metal powder. Such agents can be present at from about 1 mole percent to about 20 mole percent, preferably from about 5 mole percent to about 10 mole percent in the reaction mixture. This deprotection is performed at a temperature of from about -20°C to about 45°C. Following completion, the reaction is acidified with an aqueous acid such as HCl, acetic acid, propanoic acid, sulfuric acid, phosphoric acid, or oxalic acid to precipitate out the pharmaceutically active lactam of formula I.
- an aqueous acid such as HCl, acetic acid, propanoic acid, sulfuric acid, phosphoric acid, or oxalic acid
- Suitable alkali metal and alkaline earth metal hydroxides and carbonates for this deprotection step are as defined above.
- Suitable solvents include water, methanol, ethanol, isopropanol, acetonitrile and tetrahydrofuran.
- the mercaptoalkanoylamino lactam product of formula I is added to a suitable solvent containing a sufficient amount of an agent that minimizes the amount of the disulfides of formula III, and in turn, minimizes the formation of the undesired epimer of the pharmaceutically active compound of formula I.
- suitable agents for this purpose include bismercaptans as well as phosphine and phosphite reducing agents, zinc metal powder, and sodium hydrosulfite. Such agents can be present at from about 1 mole percent to about 20 mole percent, preferably from about 5 mole percent to about 10 mole percent in the recrystallization mixture.
- the resulting slurry is subjected to changes in temperature and/or pH, optionally filtered, and then subjected to additional changes in temperature and/or pH to effect the recrystallization.
- the slurry can be heated at from about 25°C to the reflux temperature to dissolve the solids, the solution is then filtered, the combined filtrates are cooled to about room temperature, and desired product is collected.
- the slurry is treated to raise the pH above at least about 8 by the addition of a basic material such as an alkali metal or alkaline earth metal hydroxide or carbonate, afterward the pH is lowered to at least below about 8 and preferably below about 6.0 and the product is precipitated out by the addition of an acid such as HCl, acetic acid, propanoic acid, sulfuric acid, phosphoric acid, or oxalic acid, the product is filtered off, washed with water and tert-butyl methyl ether, and dried in vacuo .
- a basic material such as an alkali metal or alkaline earth metal hydroxide or carbonate
- an acid such as HCl, acetic acid, propanoic acid, sulfuric acid, phosphoric acid, or oxalic acid
- Suitable solvents for the recrystallization process include methanol, ethanol, isopropanol and mixtures thereof.
- the bismercaptans employed in the above deprotection and recrystallization procedure are compounds which in the presence of the disulfide of formula III will cleave such disulfides by forming a stable ring.
- Suitable bismercaptans are those of the formula
- k is an integer from 1 to 4 and each X2 is independently selected from hydrogen and hydroxy as well as 1, 2-benzenedimethanethiol, 1, 3-butanedithiol meso- ⁇ , ⁇ '- dimercaptoadipic acid, disodium salt, and durene- ⁇ (l), ⁇ (2) -dithiol .
- Preferred bismercaptans are dithiothreitol and dithioerythritol .
- Suitable phosphine reducing agents include tributyl phosphine and triphenyl phosphine .
- Suitable phosphite reducing agents include triethyl phosphite.
- the preferred reagent for use in the deprotection and recrystallization reactions of this invention is dithiothreitol.
- the by-products of the disulfide of formula III are also minimized.
- Such by-products include, when R 1 is other than hydrogen, the mercaptoalkanylamino lactams of formula I having the undesired chirality at the optically active carbon in the sidechain.
- X in the acylmercaptoalkanoylamino lactam acid or ester of formula II is of formula IV or formula XV, n is zero, Rl is benzyl, and R2 is methyl.
- Xi is of formula IV
- q is preferably two
- R4, R5 , Rio, and Rn are preferably hydrogen
- b is preferably zero
- R 2 is preferably hydrogen or ethyl
- R ⁇ and R7 are preferably independently selected from hydrogen and alkyl of 1 to 4 carbons, especially where R ⁇ and R7 are both methyl.
- Xi is of formula XV
- v is preferably two
- d is preferably one
- Y5 is preferably -CH2-
- ⁇ is preferably -S-
- R12 is preferably hydrogen or methyl .
- the asterick (*) in formulas I, II and XXIV represent an asymmetric carbon in the acylmercaptoalkanoyl and mercaptoalkanoyl sidechain. In the preferred compounds, this asymmetric center has the absolute configuration S. As shown in formula IV to XXXIII other asymmetric centers are present in the various amino lactam rings .
- the pharmaceutically active products of formula I wherein R12 is hydrogen are useful cardiovascular agents particularly useful in the treatment of hypertension and congestive heart failure.
- the pharmaceutically active products can be formulated in amounts effective for treating hypertension or congestive heart failure as described by Karanewsky et al . in U.S. Patent 5,552,397, Karanewsky in U.S.
- reaction was stirred at room temperature for an additional two hours at which point TLC confirmed that the reaction was complete .
- a pH probe and a reflux condenser were attached to the reaction flask.
- the reaction was acidified with previously argon-sparged 3N HCl solution to a pH between 8 and 9. The mixture was warmed to 40°C
- the reaction was acidified with previously sparged 3N HCl to a pH of 6. A few seed crytals were added and the mixture was stirred for 5 minutes. The mixture was then further acidified to pH 2. The resulting slurry was stirred at room temperature for one hour. The product was collected by filtration and washed with distilled water until the wash-water tested negative for chloride with silver nitrate solution. The product was air-dried for 30 minutes, washed with t-butyl methyl ether
- the solution was cooled to -15°C and finely ground potassium carbonate (311.6 g, 2.25 moles) was added with agitation. After completion of the reaction (no starting material was detected by either TLC or HPLC) , the potassium carbonate was removed by filtration. The filter cake was washed with methanol (400 ml) . The temperature of the filtrate was kept at 0°C while it was transferred to another 10 1 flask. Concentrated HCl (280 ml) which had been purged with argon was added rapidly with agitation. The desired product crystallized immediately and the resulting suspension was agitated at 10°C for 30 minutes. Ice water (3.5 1) was added and the suspension was agitated at 0°C for one hour.
- the filter cake was washed with methyl tert- butyl ether (3 x 55 ml) and the filtrate was diluted with additional methyl tert-butyl ether (750 ml) .
- the organic phase was washed with dilute phosphoric acid (450 ml, 1:3 v/v of 85% phosphoric acid to water) , aqueous sodium bisulfite (3% w/v, 450 ml) , and 5% aqueous sodium chloride
- Trifluoroacetic acid (9.0 ml, 126 mmole) was added to a solution of the product from part (a) (3.75 g, 7.88 mmole) in methylene chloride (30 ml) .
- dibasic sodium phosphate (8.4 g, 59.1 mmole) dissolved in water (50 ml) was added to the reaction mixture chilled in an ice bath.
- the pH of the mixture dropped to 1.4 and was adjusted to 2.9 with ION sodium hydroxide.
- the layers were separated and the organic layer was washed with a solution of dibasic sodium phosphate (0.5 g) in water (25 ml) after adjusting its pH to 2.9 with concentrated HCl.
- the reaction was stirred at 1°C for 30 minutes, and then the ice bath was removed to allow the reaction to warm to room temperature over 1 hour .
- a pH probe and a reflux condenser were attached to the reaction flask.
- the reaction was acidified with previously sparged 3N HCl solution to pH 6.
- the reaction was warmed to 40°C (internal temperature probe) .
- a few seed crystals of the desired product were added, and the mixture was further acidified with 3N HCl with stirring to pH 2.
- the resulting slurry was stirred at 40°C for 30 minutes and then allowed to cool to room temperature over 1 hour.
- the product was collected by filtration and washed with distilled water (about 30 ml) until the wash-water tested negative for chloride with silver nitrate solution.
- the product solution was polish filtered to remove any particles, and the hydrolysis vessel and polish filter were washed with water (50 g) .
- the filtrates were combined in a 1 liter four necked flask equipped with a mechanical stirrer, pH electrode, thermocouple and argon inlet. With vigorous agitation, the title compound was crystallized at 20° ⁇ 10°C by the addition of degassed IN acetic acid (401 g, dissolved oxygen level is less than or equal to 5%) to a final pH of 5.5 ⁇ 0.5.
- the crystal slurry was agitated at 20 ⁇ 10°C for at least one hour, collected on a filter (inert atmosphere was no longer employed) , and the wet-cake was washed with water (3 x 100 g) .
- the wet-cake was dried in vacuo to afford 45.1 g of title product as a white crystalline powder having the same analytical values as in Example 1.
- Degassed alcohol solution (302 g of absolute ethanol and 87 g of methanol, containing less than or equal to 5% oxygen) was added to a 1 liter flask equipped with a mechanical stirrer, reflux condenser, thermocouple, and an argon inlet, containing [4S- [4 ⁇ (R* ) , 7 ⁇ , lOa ⁇ ] ] -octahydro-
- the crystal slurry was stirred at 41° to 46°C for 20 minutes and then allowed to cool to room temperature. After stirring at room temperature for 30 minutes, the product was filtered and washed with water (100 ml) and dried in a vacuum oven at 51°C/4.1 inch Hg to afford 8.45 g of title product having laboratory HPLC of 99.75 area percent.
- the product from part (a) (5g) , D, -dithiothreitol (130 mg) and deoxygenated water (18 ml) were charged to a reaction vessel. Under an inert atmosphere, the mixture was stirred at ambient temperature and a solution of sodium hydroxide (17.5 ml, approximately 2.2 N) was charged while maintaining the temperature between 21 and 25°C. A clear solution was observed for 5 minutes after the sodium hydroxide had been added and the reaction mixture was stirred until the reaction was judged complete by HPLC assay. The solution was heated to 45°C and deoxygenated acetic acid (43 ml, approximately 1 N) was added to adjust the pH of the product slurry to 5.9.
- the product was crystallized by the addition of deoxygenated aqueous acetic acid (1.5 equivalents) which was prepared by dissolving glacial acetic acid (11.11 g, 10.59 ml, 186.8 mmol) in deionized water (175.7 ml) and was then deoxygenated by being bubbled with nitrogen.
- the acetic acid solution was added over 10 - 15 minutes and the pH fell from 8.1 to 7.2.
- additional deoxygenated IN acetic acid was added over 10 to 15 minutes to complete the crystallization.
- the final pH of the slurry was 5.3.
- the product slurry was stirred for 1 hour at 15 - 25°C, filtered, and washed with water and tert-butyl methyl ether.
- the desired product was dried under vacuum at 35 - 45°C for 16 hours to give 49.39 g of product (98% weight yield) having a purity of greater than 99%.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002317718A CA2317718A1 (en) | 1998-01-06 | 1998-12-11 | Deprotection and recrystallization processes |
JP2000527544A JP2002500224A (en) | 1998-01-06 | 1998-12-11 | Deprotection and recrystallization method |
AU18207/99A AU745379B2 (en) | 1998-01-06 | 1998-12-11 | Deprotection and recrystallization processes |
EP98963113A EP1051419A4 (en) | 1998-01-06 | 1998-12-11 | Deprotection and recrystallization processes |
KR1020007007451A KR20010085182A (en) | 1998-01-06 | 1998-12-11 | Deprotection and Recrystallization Processes |
HU0101191A HUP0101191A3 (en) | 1998-01-06 | 1998-12-11 | Deprotection and recrystallization processes |
IL13636198A IL136361A0 (en) | 1998-01-06 | 1998-12-11 | Processes for preparing mercaptoalkanoylamino lactam acids and esters thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7057398P | 1998-01-06 | 1998-01-06 | |
US60/070,573 | 1998-01-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999035145A1 true WO1999035145A1 (en) | 1999-07-15 |
Family
ID=22096136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/026443 WO1999035145A1 (en) | 1998-01-06 | 1998-12-11 | Deprotection and recrystallization processes |
Country Status (10)
Country | Link |
---|---|
US (3) | US6340752B1 (en) |
EP (1) | EP1051419A4 (en) |
JP (1) | JP2002500224A (en) |
KR (1) | KR20010085182A (en) |
AU (1) | AU745379B2 (en) |
CA (1) | CA2317718A1 (en) |
HU (1) | HUP0101191A3 (en) |
IL (1) | IL136361A0 (en) |
TW (1) | TW515800B (en) |
WO (1) | WO1999035145A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6162913A (en) * | 1998-07-15 | 2000-12-19 | Bristol-Myers Squibb Co. | Preparation of [4S-(4α,7α,10aβ)]-4-amino-octahydro-5-oxo-7H-pyrido[2,1 -b] [1,3]thiazepine-7-carboxylic acid, methyl ester and salts thereof via novel disulfides |
US6166227A (en) * | 1998-07-15 | 2000-12-26 | Bristol-Myers Squibb Co. | Preparation of (S)-2-amino-6, 6-dimethoxyhexanoic acid methyl ester via novel dioxolanes |
EP1235792A1 (en) * | 1999-07-29 | 2002-09-04 | Bristol-Myers Squibb Company | Preparation of [4s-(4alpha,7alpha,10abeta)]-4-amino-octahydro-5-oxo-7h-pyrido 2,1-b] 1,3]thiazepine-7-carboxylic acid, methyl ester and salts thereof via novel disulfides |
US6620600B2 (en) | 2000-09-15 | 2003-09-16 | Bristol-Myers Squibb Co. | Enzymatic resolution of aryl and thio-substituted acids |
US6770640B1 (en) | 1998-12-31 | 2004-08-03 | Aventis Pharmaceuticals Inc. | 1-Carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of MMP-12 |
WO2024103123A1 (en) * | 2022-11-17 | 2024-05-23 | Endothelium Scanning Nanotechnology Limited | The synthesis of omapatrilat |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525723A (en) * | 1993-11-18 | 1996-06-11 | Bristol-Myers Squibb Co. | Compounds containing a fused multiple ring lactam |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552397A (en) | 1992-05-18 | 1996-09-03 | E. R. Squibb & Sons, Inc. | Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase |
RU2124503C1 (en) * | 1992-05-18 | 1999-01-10 | И.Р.Сквибб энд Санз, Инк. | Heterocyclic nitrogen-containing derivatives of carboxylic acid, method of their synthesis, pharmaceutical composition |
US5504080A (en) | 1992-10-28 | 1996-04-02 | Bristol-Myers Squibb Co. | Benzo-fused lactams |
US5508272A (en) * | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
US5362727A (en) | 1993-07-26 | 1994-11-08 | Bristol-Myers Squibb | Substituted azepino[2,1-a]isoquinoline compounds |
US5587375A (en) | 1995-02-17 | 1996-12-24 | Bristol-Myers Squibb Company | Azepinone compounds useful in the inhibition of ACE and NEP |
US5877313A (en) | 1995-05-17 | 1999-03-02 | Bristol-Myers Squibb | Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP |
US5650408A (en) | 1995-06-07 | 1997-07-22 | Karanewsky; Donald S. | Thiazolo benzazepine containing dual action inhibitors |
US5635504A (en) | 1995-06-07 | 1997-06-03 | Bristol-Myers Squibb Co. | Diazepine containing dual action inhibitors |
-
1998
- 1998-12-09 US US09/208,135 patent/US6340752B1/en not_active Expired - Fee Related
- 1998-12-11 EP EP98963113A patent/EP1051419A4/en not_active Withdrawn
- 1998-12-11 HU HU0101191A patent/HUP0101191A3/en unknown
- 1998-12-11 AU AU18207/99A patent/AU745379B2/en not_active Ceased
- 1998-12-11 IL IL13636198A patent/IL136361A0/en unknown
- 1998-12-11 JP JP2000527544A patent/JP2002500224A/en active Pending
- 1998-12-11 WO PCT/US1998/026443 patent/WO1999035145A1/en not_active Application Discontinuation
- 1998-12-11 KR KR1020007007451A patent/KR20010085182A/en not_active Application Discontinuation
- 1998-12-11 CA CA002317718A patent/CA2317718A1/en not_active Abandoned
- 1998-12-30 TW TW087121917A patent/TW515800B/en not_active IP Right Cessation
-
2001
- 2001-11-16 US US09/991,408 patent/US6444810B1/en not_active Expired - Fee Related
- 2001-11-16 US US09/993,872 patent/US6486315B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525723A (en) * | 1993-11-18 | 1996-06-11 | Bristol-Myers Squibb Co. | Compounds containing a fused multiple ring lactam |
Non-Patent Citations (8)
Title |
---|
KLILES J W, ET AL.: "ANGIOTENSIN-CONVERTING ENZYME INHIBITORS: NEW ORALLY ACTIVE 1,4-THIAZEPINE-2,5-DIONES, 1,4-THIAZINE-2,5-DIONES, AND 1,4-BENZOTHIAZEPINE-2,5-DIONES POSSESSING ANTIHYPERTENSIVE ACTIVITY", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 29, no. 05, 1 January 1986 (1986-01-01), US, pages 784 - 796, XP002917039, ISSN: 0022-2623, DOI: 10.1021/jm00155a032 * |
MARTIN T A, COMER W T: "N-¬¬MERCAPTOACATY(AMINO¾NEZOYL¾GLUCINES AS MUCOLYTIC AGENTS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 28, no. 07, 1 January 1985 (1985-01-01), US, pages 910 - 914, XP002917041, ISSN: 0022-2623, DOI: 10.1021/jm00145a011 * |
NARDI D, ET AL.: "NUOVE 2,4-DIBROMO-6(N-CICLOESIL-N-METIL)AMINO-METHILANILIDI DI DERIVATI DELLA CISTEINA E DELLA CISTINA AD ATTIVITA ESPETTORANTE", FARMACO, EDIZIONE SCIENTIFICA., SOCIETA CHIMICA ITALIANA, PAVIA., IT, vol. 40, no. 02, 1 January 1985 (1985-01-01), IT, pages 108 - 119, XP002917040, ISSN: 0430-0920 * |
PODKOSCIELNY W, KOWALEWSKA W, BAKUNIAK E: "SYNTEZA, STUKTURA ORAZ FIZYKOCHEMICNE I BIOLOGICZNE WLASCIWOSCI N-(3-I 5-ACENAFTYLO)-ALPHA-MERKAPTOACETAMIDOW", PRZEMYSL CHEMICZNY, WYDAWNICTWO SIGMA, PL, vol. 73, no. 08, 1 January 1994 (1994-01-01), PL, pages 304/305, XP002917038, ISSN: 0033-2496 * |
ROBI J A, ET AL.: "DUAL METALLOPROTEASE INHIBITORS. 6. INCORPORATION OF BICYELIC AND SUBSTITUTED MONOCYCLIC AZEPINONES AS DIPEPTIDE SURROGATES IN ANGIOTENSIN-CONVERTING ENZYME/NEUTRAL ENDOPEPTIDASE INHIBITORS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 39, no. 02, 1 January 1996 (1996-01-01), US, pages 494 - 502, XP002917036, ISSN: 0022-2623, DOI: 10.1021/jm950677a * |
See also references of EP1051419A4 * |
SUK-WAH, TAM-CHANG: "SELF-ASSEMBLED MONOLAYERS ON GOLD GENERATED FORM ALKANETHIOLS WITH THE STRUCTURE RNHCOCH2SH", LANGMUIR, AMERICAN CHEMICAL SOCIETY, US, vol. 11, 1 January 1995 (1995-01-01), US, pages 4371 - 4382, XP002917037, ISSN: 0743-7463, DOI: 10.1021/la00011a033 * |
WARSHAWSKY A M, ET AL.: "THE SYNTHESIS OF AMINOBENZAZEPINONES AS ANTI-PHENYLALANINE PIPEPTIDE MINICS AND THEIR USE IN NEP-INHIBITION", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 06, no. 08, 1 January 1996 (1996-01-01), AMSTERDAM, NL, pages 957 - 962, XP002917035, ISSN: 0960-894X, DOI: 10.1016/0960-894X(96)00149-7 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6162913A (en) * | 1998-07-15 | 2000-12-19 | Bristol-Myers Squibb Co. | Preparation of [4S-(4α,7α,10aβ)]-4-amino-octahydro-5-oxo-7H-pyrido[2,1 -b] [1,3]thiazepine-7-carboxylic acid, methyl ester and salts thereof via novel disulfides |
US6166227A (en) * | 1998-07-15 | 2000-12-26 | Bristol-Myers Squibb Co. | Preparation of (S)-2-amino-6, 6-dimethoxyhexanoic acid methyl ester via novel dioxolanes |
US6248882B1 (en) | 1998-07-15 | 2001-06-19 | Bristol-Myers Squibb Co. | Preparation of (s)-2-amino-6,6-dimethoxyhexanoic acid methyl ester via novel dioxolanes |
US6329542B1 (en) | 1998-07-15 | 2001-12-11 | Bristol-Myers Squibb Co. | Preparation of (S)-2-amino-6,6-dimethoxyhexanoic acid methyl ester via novel dioxolanes |
US6770640B1 (en) | 1998-12-31 | 2004-08-03 | Aventis Pharmaceuticals Inc. | 1-Carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of MMP-12 |
EP1235792A1 (en) * | 1999-07-29 | 2002-09-04 | Bristol-Myers Squibb Company | Preparation of [4s-(4alpha,7alpha,10abeta)]-4-amino-octahydro-5-oxo-7h-pyrido 2,1-b] 1,3]thiazepine-7-carboxylic acid, methyl ester and salts thereof via novel disulfides |
EP1235792A4 (en) * | 1999-07-29 | 2003-06-25 | Bristol Myers Squibb Co | Preparation of [4s-(4alpha,7alpha,10abeta)]-4-amino-octahydro-5-oxo-7h-pyrido 2,1-b] 1,3]thiazepine-7-carboxylic acid, methyl ester and salts thereof via novel disulfides |
US6620600B2 (en) | 2000-09-15 | 2003-09-16 | Bristol-Myers Squibb Co. | Enzymatic resolution of aryl and thio-substituted acids |
US7026143B2 (en) | 2000-09-15 | 2006-04-11 | Bristol-Myers Squibb Company | Enzymatic resolution of aryl and thio-substituted acids |
US7141694B2 (en) | 2000-09-15 | 2006-11-28 | Bristol-Myers Squibb Company | Enzymatic resolution of aryl and thio-substituted acids |
WO2024103123A1 (en) * | 2022-11-17 | 2024-05-23 | Endothelium Scanning Nanotechnology Limited | The synthesis of omapatrilat |
Also Published As
Publication number | Publication date |
---|---|
CA2317718A1 (en) | 1999-07-15 |
EP1051419A1 (en) | 2000-11-15 |
HUP0101191A3 (en) | 2002-06-28 |
TW515800B (en) | 2003-01-01 |
US20020086994A1 (en) | 2002-07-04 |
US20020086995A1 (en) | 2002-07-04 |
KR20010085182A (en) | 2001-09-07 |
IL136361A0 (en) | 2001-06-14 |
US6340752B1 (en) | 2002-01-22 |
AU745379B2 (en) | 2002-03-21 |
US6444810B1 (en) | 2002-09-03 |
JP2002500224A (en) | 2002-01-08 |
US6486315B2 (en) | 2002-11-26 |
HUP0101191A2 (en) | 2001-09-28 |
EP1051419A4 (en) | 2002-08-28 |
AU1820799A (en) | 1999-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2179407C (en) | Process for the preparation of leukotriene antagonists | |
AU661616B2 (en) | Benzo-fused lactams | |
EP1615947A2 (en) | Process for preparing macrocyclic compounds | |
CZ2005427A3 (en) | Process for preparing hemi-calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenoic acid | |
EP2125783A2 (en) | Process for the preparation of esomeprazole magnesium dihydrate | |
CA2764425C (en) | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid | |
EP1051419A1 (en) | Deprotection and recrystallization processes | |
TW200825056A (en) | New compounds | |
JPH04261175A (en) | Preparation of beta-lactam having acetyl side chain substituted by aminothiazole- (iminooxyacetate) and its intermediate | |
CA2151384A1 (en) | Benzazepinone derivatives | |
KR101316653B1 (en) | Manufacturing Method Of Hetero Cyclic Compound | |
US6306886B1 (en) | Crystalline roxifiban | |
MXPA00006014A (en) | Deprotection and recrystallization processes | |
JP4307594B2 (en) | Method for isolating 1- [N2-((S-ethoxycarbonyl) -3-phenylpropyl) -N6-trifluoroacetyl] -L-lysyl-L-proline and isolated product thereof | |
US6642388B1 (en) | Method for producing 2-aminomethyl-4-cyano-thiazol | |
KR100372757B1 (en) | Sulfonamide Derivative as a Matrix Metalloproteinase Inhibitor | |
SI8811355A (en) | Process for preparing of L-alanine-L-proline derivatives | |
HUT67489A (en) | Loracarbef hydrochloride c1-c3 alcohol solvates and uses thereof | |
KR100405913B1 (en) | Biphenyl Butyric Acid Derivative as a Matrix Metalloproteinase Inhibitor | |
KR100194158B1 (en) | Method for preparing 1- (D-3-acetylthio-2-methylpropanoyl) -L-proline-L-phenylalanine | |
KR20040092058A (en) | Manufacture method of Erdosteine | |
JPH0222262A (en) | Production of alkylated amide derivative | |
KR20130140296A (en) | Method for preparing crystalline form iii of temocapril hydrochloride | |
MXPA99011753A (en) | Crystalline roxifiban | |
JPH08176131A (en) | Production of optically active 3-(paraalkoxyphenyl) glycidic acid ester derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 136361 Country of ref document: IL |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/006014 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 527544 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2317718 Country of ref document: CA Ref country code: CA Ref document number: 2317718 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18207/99 Country of ref document: AU Ref document number: 1020007007451 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998963113 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998963113 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007007451 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 18207/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998963113 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007007451 Country of ref document: KR |